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ORIGINAL ARTICLE
Toxicity at three years with and without irradiation of the internal 
mammary and medial supraclavicular lymph node chain in stage I to 
III breast cancer (EORTC trial 22922/10925)
OSCAR MATZINGER1,2, IRMA HEIMSOTH3, PHILIP POORTMANS4, 
LAURENCE COLLETTE1, HENK STRUIKMANS5, WALTER VAN DEN BOGAERT6, 
ALAIN FOURQUET7, HARRY BARTELINK8, FATMA ATAMAN9 †, AKOS GULYBAN1, 
MARIANNE PIERART1 AND GEERTJAN VAN TIENHOVEN10 FOR THE EORTC 
RADIATION ONCOLOGY & BREAST CANCER GROUPS 
1European Organisation for Research and Treatment of Cancer (EORTC), Headquarters, Brussels, Belgium, 2Department of 
Radiation Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, 3Department of Radiation 
Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands, 4Department of Radiation Oncology, Dr. Bernard 
Verbeeten Institut, Tilburg, The Netherlands, 5Department of Radiation Oncology, Leiden University Medical Centre, Leiden, 
The Netherlands, 6Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium, 7Department of 
Radiation Oncology, Institut Curie, Paris, France, 8Department of Radiation Oncology, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands, 9Department of Radiation Oncology, Süleyman Demirel University, Isparta, Turkey and 
10Department of Radiation Oncology, Academic Medical Centre, Amsterdam, The Netherlands. 
Abstract
Introduction. The EORTC 22922/10925 trial investigated the potential survival benefi t and toxicity of elective irradiation 
of the internal mammary and medial supraclavicular (IM-MS) nodes Accrual completed in January 2004 and fi rst results 
are expected in 2012. We present the toxicity reported until year 3 after treatment. Patients and methods. At each visit, 
toxicity was reported but severity was not graded routinely. Toxicity rates and performance status (PS) changes at three 
years were compared by χ2 tests and logistic regression models in all the 3 866 of 4 004 patients eligible to the trial 
who received the allocated treatment. Results. Only lung (fi brosis; dyspnoea; pneumonitis; any lung toxicities) (4.3% vs. 
1.3%; p  0.0001) but not cardiac toxicity (0.3% vs. 0.4%; p  0.55) signifi cantly increased with IM-MS treatment. 
No signifi cant worsening of the PS was observed (p  0.79), suggesting that treatment-related toxicity does not impair 
patient’s daily activities. Conclusions. IM-MS irradiation seems well tolerated and does not signifi cantly impair WHO PS 
at three years. A follow-up period of at least 10 years is needed to determine whether cardiac toxicity is increased after 
radiotherapy. 
Many studies on lymphatic drainage of the breast 
confi rmed the importance of the Internal Mammary 
(IM) basin as a second draining route in breast cancer 
[1–3]. The incidence of lymph node (LN) metastasis 
of the internal mammary and medial supraclavicular 
(IM-MS) lymph node chain ranges between 4–9% in 
axillary node negative patients and 16–52% for axil-
lary node positive patients [4–6]. A recent analysis of 
2 269 Chinese breast cancer patients examined the 
subpopulation with high risk of internal mammary 
lymph nodes metastasis [7]. They described inci-
dences of IM metastasis in more than 20% of patients 
with the following conditions: (1) patients with four 
or more positive axillary LN, (2) Patients with medial 
tumour and positive axillary LN, (3) Patients with T3 
tumour and younger than 35 years, (4) Patients with 
T2 tumour and positive axillary LN and (5) Patients 


















































 Early toxicity after IM-MS irradiation 25
and 24 Gy was delivered with electrons. To enable 
many radiotherapy institutes to participate in the 
trial and to accrue a large and representative sam-
ple of patients, a standard treatment technique 
with one anterior fi eld for the IM-MS irradiation 
was recommended. The IM-MS lymph node area 
had to be treated with mixed photon and electron 
beams matched to the tangential field borders of 
the breast or thoracic wall (which could alterna-
tively be treated with a direct electron field). Sev-
eral institutes had developed specific irradiation 
techniques in this indication [12]. These more 
complex treatment set-ups were accepted in the 
trial, provided that they took into account the indi-
vidual localisation of the internal mammary nodes 
[12,13]. 
The defi ned organs at risk were the lungs and the 
heart.  No specifi c constraints were however defi ned 
in the protocol as the irradiated lung and heart vol-
umes were considered as limited by the use of the 
mixed beam technique.  
This study was subjected to an intensive quality 
assurance programme consisting of a dummy run 
and individual case review. The results of this proce-
dure were already previously reported [11–15].
The protocol contained no guidelines which 
patients were to receive adjuvant treatment (hor-
monotherapy, chemotherapy).
Data collection
At the time of randomisation, data on WHO perfor-
mance status (PS), tumour characteristics, number 
of positive axillary nodes and on adjuvant systemic 
treatment were collected for each patient. The fol-
lowing details concerning the radiotherapy were col-
lected after completion of treatment: duration and 
interruption of radiotherapy, total dose, number of 
fractions and the technique used for IM-MS chain 
treatment. Yearly follow-up visit documented PS, 
presence of lung fi brosis, presence of cardiac fi brosis, 
presence of other toxicity and evidence of cardiac 
disease. Other toxicities and cardiac disease were to 
be detailed in free text. 
Thoracic x-ray was obtained as a part of the 
yearly loco-regional evaluation in the protocol. Ejec-
tion fraction study was optional.
Statistical methods
The analysis was conducted in the per protocol pop-
ulation of patients who were eligible to the protocol 
and followed the randomly allocated IM-MS treat-
ment policy. Patients with partial IM-MS irradiation 
were also excluded.
IM lymph node dissection was therefore per-
formed in a number of institutes in the 1950s and 
1960s. This radical surgical procedure was aban-
doned in the 1970s because several studies showed 
that this approach did not improve survival [8]. How 
to interpret today the clinical relevance of the historic 
rates of IM lymph node involvement in view of 
the greater proportion of screen-detected cancers, 
the improved imaging for detection of IM-nodes 
involvement, the increasing use of adjuvant systemic 
therapy and the newer radiotherapy techniques is 
unclear. 
The interest for an elective treatment of the 
IM-MS nodes was renewed after the publication of 
several prospective randomised trials that demon-
strated a favourable outcome after elective loco-
regional irradiation [9,10]. In operable breast cancer 
however, the role of regional radiotherapy of the 
IM-MS chain remains controversial [8] since defi nite 
evidence supporting that elective irradiation of espe-
cially the IM nodes improves overall survival is lack-
ing. Whether the expected benefi t of elective 
irradiation of the IM-MS nodes counterbalances a 
possible increase of the risk of late toxicity is still 
unresolved [5]. 
The Radiation Oncology Group and the Breast 
Cancer Group of the European Organisation for 
Research and Treatment of Cancer (EORTC) there-
fore initiated a large randomised phase III multi-
centre trial (EORTC 22922/10925) assessing the 
impact of elective IM-MS lymph node irradiation on 
overall survival in patients with localised, stage I–III, 
breast cancer with medially or centrally located 
tumours and/or axillary lymph node invasion. This 
trial that recruited patients between July 1996 and 
January 2004, enrolled 4 004 women with unilateral 
breast cancer after breast and axillary surgery. The 
fi rst analysis of the primary endpoint, overall survival 
at 10 years, will be performed about eight years after 
recruitment of the last patient, which is expected to 
be in 2012. Extensive reviews on the study popula-
tion [11], on the radiotherapy techniques [12] as well 
as on the quality assurance program [13–15] have 
already been published.
We present here the toxicity reported up to three 
years after treatment as well as the change in WHO 




The prescribed dose was 50 Gy in 25 fractions of 
2 Gy; 26 Gy was delivered with photons (minimum 
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The percentage of patients with any toxicity 
reported in the fi rst three years after treatment was 
compared between the two treatment arms by means 
of χ2 tests. The events reported as free text were also 
grouped by category for descriptive purposes. The 
rates of individual events related to “lung toxicity” as 
well as the rates of any lung-related toxicity, the rates 
of cardiac disease, cardiac fi brosis and those of any 
skin-related toxicities were also formally compared 
by means of χ2 tests between the treatment groups. 
To adjust the risk of false positive fi ndings for the 
multiplicity of the tests, a nominal signifi cance level 
of 0.01 was used.
Furthermore, changes in WHO performance sta-
tus between randomisation and year 3 of the fol-
low-up were assessed as no change, improvement or 
worsening. To avoid confounding the worsening of 
the PS related by the deterioration due to progressive 
disease, patients with disease progression reported 
within three years of entry on study were excluded 
from the analysis. Because patients with WHO PS of 
0 at entry could not improve their performance sta-
tus, we studied the probability of PS deterioration. 
Univariate and multivariate logistic regression 
models were used to assess the impact of treatment 
arm (IM-MS vs. no IM-MS), laterality of the breast 
cancer (left vs. right), adjuvant hormonotherapy 
(yes vs. none reported), neo-adjuvant chemotherapy 
(yes vs. no), age (45 years vs. 45-55 years vs. 
55-65 vs. 65 y), type of surgery (lumpectomy vs. 
mastectomy), tumour size (in centimetres), patho-
logical axillary nodal status (pN vs. pN0), oestro-
gen and progesterone receptor status (positive vs. 
negative) and menopausal status (post-menopausal/
artifi cial menopause vs. pre-menopausal) as possible 
predictors of the worsening of the PS.  Statistical 
signifi cance in these models was set at 5%. 
Furthermore, we assessed the correlation between 
the presence of toxicity and the deterioration of the 
performance status using univariate logistic regres-
sion models as above mentioned.
Because of the very large sample size, the statisti-
cal power is very high and statistical signifi cance 
may not necessarily indicate clinically meaningful 
differences.
Results
We report on the prospectively collected data from 
3 866 of the 4 004 patients randomised (97%) in the 
IM-MS EORTC study 22922/10925 who were 
eligible and followed the allocated treatment policy 
(no IM-MS irradiation: N  1944 vs. IM-MS irra-
diation: N  1922). Complete follow-up documen-
tation up to year 3 was available for 95.3% of the 








Age (years)   
 Median 54.0 54.0 
 Range 22.0 - 75.0 19.0 - 75.0 
 45  346 (17.8)  354 (18.4) 
45-55  680 (35.0)  661 (34.4) 
55-65  582 (29.9)  579 (30.1) 
65  336 (17.3)  328 (17.1) 
Performance Status (PS)   
 PS 0 1733 (89.1) 1725 (89.8) 
 PS 1  198 (10.2)  181 (9.4) 
 PS 2   7 (0.4)    5 (0.3) 
 Missing   6 (0.3)   11 (0.6) 
Menopausal status   
 Pre-menopausal  650 (33.4)  657 (34.2) 
 Peri-menopausal 151 (7.8)  133 (6.9) 
 Post menopausal 1080 (55.6) 1071 (55.7) 
 Artifi cial menopause  63 (3.2)  61 (3.2) 
Type of breast surgery   
 Mastectomy  447 (23.0)  454 (23.6) 
 Breast conserving 1497 (77.0) 1468 (76.4) 
Pathological T *   
 pT1 1180 (60.7) 1160 (60.4) 
 pT2  689 (35.4)  685 (35.6) 
 pT3  65 (3.3)  70 (3.6) 
 Missing  10 (0.5)    7 (0.4) 
Pathological N (axilla)∗   
 pN0  877 (45.1)  855 (44.5) 
 pN1  848 (43.6)  822 (42.8) 
 pN2  182 (9.4)  188 (9.8) 
 pN3  37 (1.9)  57 (3.0) 
Tumour stage∗   
 Stage I  658 (33.8)  654 (34.0) 
 Stage IIa  647 (33.3)  612 (31.8) 
 Stage IIb  376 (19.3)  374 (19.5) 
 Stage III  253 (13.0)  276 (14.4) 
 Missing  10 (0.5)   6 (0.3) 
Combination of ER/PR status   
 ER, PR 1066 (54.8) 1055 (54.9) 
 ER, PR-/unknown  359 (18.5)  380 (19.8) 
 PG, ER-/unknown  82 (4.2)  66 (3.4) 
 ER-, PR-  320 (16.5)  295 (15.3) 
 Missing 117 (6.0) 126 (6.6) 
Adjuvant hormonal therapy   
 None reported  775 (39.9)  786 (40.9) 
 yes 1169 (60.1) 1136 (59.1) 
Adjvuant chemotherapy   
 No chemotherapy  886 (45.6)   871 (45.3) 
 Adjuvant  243 (12.5)   242 (12.6) 
 Neo-adjuvant  815 (41.9)   809 (42.1) 
Adjuvant treatment   
 None  294 (15.1)   316 (16.4) 
 Chemotherapy  481 (24.7)   470 (24.5) 
 Hormonal therapy  592 (30.5)   555 (28.9) 
 Both  577 (29.7)   581 (30.2) 
∗Staging is according to UICC 1992 
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treatment arm vs. 84.1% after IM-MS irradiation. 
It deteriorated in 141 of 1 944 (8.4%) vs. 144 of 
1 657 (8.7%) of the patients in the standard and 
IM-MS treatment arm, respectively and improved in 
8.3% vs. 7.2%, respectively. There was no signifi cant 
difference between the two treatment arms (p  
0.79). Respectively 133 of 141 and 134 of 144 of 
the deteriorations of the PS were in the form of 
an increase from PS 0 to PS 1. Conversely, all 
improvements (139 and 119 patients, respectively) 
were in the form of decrease of an initial PS 1 to a 
PS of 0.
In the whole group, the univariate analysis revealed 
a statistically signifi cant impact of the application of 
any adjuvant systemic treatment (OR  0.39, CI: 
0.30–0.52; p  0.0001) on the risk of deterioration of 
the WHO PS and no signifi cant difference between 
the two randomised treatment arms (OR1.03, CI: 
0.81–1.32, p  0.79). In order to elucidate the appar-
ently protective impact of adjuvant systemic treat-
ment, we then separated the patient group who had 
received neo-adjuvant chemotherapy) from the others 
(i.e. no adjuvant chemotherapy and adjuvant chemo-
therapy). This was in order to avoid a possible differ-
ential effect of other factors in the group neo-adjuvant 
chemotherapy, which might have had an acute and 
temporary PS deterioration at the time of randomisa-
tion, due to the neo-adjuvant chemotherapy (see Table 
IV). These analyses revealed a statistically signifi cant 
impact of adjuvant hormonotherapy in the patient 
group that did not receive neo-adjuvant chemotherapy 
(OR  0.56, CI: 0.44–0.76; p  0.0001) indicating a 
lower risk of deterioration of the WHO PS for the 
patients who received adjuvant hormonotherapy. This 
parameter was the only one that remained signifi cant 
in a multivariate model. Oestrogen and progesterone 
receptor status were also signifi cant in the univariate 
model (OR  1.06, CI: 0.69–1.63; p  0.005 vs. OR 
 0.81, CI: 0.58–1.12; p  0.025 respectively) but 
their effect vanished in the multivariate model. The 
other tested variables did not infl uence the evolution 
of the PS. In the group who received neo-adjuvant 
chemotherapy, only age was (borderline) statistically 
signifi cant in the univariate analysis, and none of the 
factors was signifi cant at the p  0.05 signifi cance 
level in the multivariate model. Table V displays a mul-
tivariate model combining all patients in one model, 
that also includes the factors that are nowadays con-
sidered in the decision to deliver neo-adjuvant chemo-
therapy or adjuvant hormonotherapy, namely disease 
stage, age, hormone receptor statuses, and meno-
pausal status. The model confi rms that in patients who 
have otherwise similar age, menopausal status, oestro-
gen and progesterone receptor status and disease 
stage, those who did receive either adjuvant hormono-
therapy or neo-adjuvant chemotherapy, as appropriate 
patients. The characteristics of the patients included 
in this analysis are presented in Table I. At entry on 
study, 89.4% of the patients presented a WHO per-
formance status of 0, 9.8% with WHO PS 1 and 12 
patients had a WHO PS of 2 (0.3%), WHO PS was 
missing in 17 (0.4%). Further details on the total 
study population were previously published [11].
Toxicity within three years of treatment
The reported toxicity per treatment arm is sum-
marised in Table II. Both study treatment arms were 
well tolerated with little toxicity: the most frequent 
reported toxicities were oedema (7.8% vs. 8.1%), 
skin fi brosis (8.3% vs. 8.5%), teleangectasia (1.5% 
vs. 2.3%) and lung fi brosis (0.9% vs. 2.8%) in the 
standard and the IM-MS arm, respectively.
There were no statistically signifi cant differences 
between the two randomised groups in terms of car-
diac fi brosis (0.3% vs. 0.4%; p  0.55) nor in terms 
of presence of “cardiac disease” (1.4% vs. 1.6%; p  
0.64). Lung fi brosis (0.9% vs. 2.8%; p  0.0001), 
dyspnoea (0.1% vs. 0.7%; p  0.0007) and pneu-
monitis (0.1% vs. 0.7%; p  0.0012) were statisti-
cally signifi cantly increased in the IM-MS treatment 
arm. This translated into a signifi cantly higher rate 
of “any lung” toxicities in the IM-MS treatment arm 
as compared to the control arm (4.3% vs. 1.3%; p  
0.0001). The observed difference represents an addi-
tional 57 cases of lung toxicity in the IM-MS arm. 
No statistically signifi cant difference could be 
observed in skin toxicity (including fi brosis, hyper-
pigmentation, teleangectasia as well as other skin 
toxicities; p  0.37). The total number of events of 
toxicity reported up to year 3 amounts 21.8% in the 
standard treatment arm vs. 25.5% in the IM-MS 
arm (67 cases,  3.7%). This difference is statisti-
cally signifi cant (p  0.006).
All other reported toxicities (mastitis, breast 
infection, radionecrosis, osteonecrosis, oedema, pain, 
dysphagia, fatigue, arm/shoulder function impair-
ment, other) were equally distributed between the 
two treatment arms.
Change in performance status at three years after 
randomisation
The PS at baseline and at year 3 is summarised in 
Table III for all 3 866 patients. Since those whose 
disease progressed or were lost to follow-up were 
censored for the assessment of WHO PS at 3 years, 
3 341 patients are included in this analysis (1 684 
and 1 657, respectively). At year 3, the WHO PS 
was unchanged compared to baseline in the majority 
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N (%) N (%) P-value
Lung Fibrosis (to year 3)∗  17 (0.9)  54 (2.8) 0.0001
Cough  5 (0.3)  10 (0.5) 0.19
Dyspnoea  1 (0.1)  14 (0.7) 0.0007
Pneumonitis  1 (0.1)  13 (0.7) 0.0012
Pleuritis  5 (0.3)  2 (0.1) 0.26
Other lung toxicity  2 (0.1)  4 (0.2) 0.41
Any lung toxicity  26 (1.3)  83 (4.3) 0.0001
Dermatitis  38 (2.0)  26 (1.4) 
Skin fi brosis   
 Yes, unspecifi ed  160 (8.2)  152 (7.9) 
 Breast/chestwall  0 (0.0)  6 (0.3) 
 Matchline  1 (0.1)  5 (0.3) 
Hyperpigmentation   
 Yes, unspecifi ed  55 (2.8)  56 (2.9) 
 Parasternal  0 (0.0)  3 (0.2) 
Teleangectasia   
 Yes, unspecifi ed  27 (1.4)  41 (2.1) 
 Parasternal  0 (0.0)  1 (0.1) 
 Supraclavicular  1 (0.1)  2 (0.1) 
Skin - other  7 (0.4)  11 (0.6) 
Any (breast) skin toxicity  246 (12.7)  262 (13.6) 0.37
Cardiac fi brosis (to year 3)∗  5 (0.3)  7 (0.4) 0.55
Evidence of cardiac disease (to year 3)∗  28 (1.4)  31 (1.6) 0.64
Mastitis  7 (0.4)  6 (0.3) 
Breast Infection  4 (0.2)  3 (0.2) 
Radionecrosis  2 (0.1)  1 (0.1) 
Osteonecrosis  22 (1.1)  27 (1.4) 
Oedema   
 Yes, unspecifi ed  81 (4.2)  81 (4.2) 
 Presternal  0 (0.0)  1 (0.1) 
 Arm/hand  70 (3.6)  73 (3.8) 
Breast/chestwall pain  45 (2.3)  35 (1.8) 
Retrosternal pain  1 (0.1)  2 (0.1) 
Other pain  15 (0.8)  26 (1.4) 
Dysphagia  0 (0.0)  4 (0.2) 
Fatigue  20 (1.0)  22 (1.1) 
Arm or shoulder function impairment  8 (0.4)  1 (0.1) 
Other  - unspecifi ed  8 (0.4)  8 (0.4) 
Any toxicity (to year 3)  424 (21.8)  491 (25.5) 0.006
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are at lower risk of PS deterioration at year 3 than 
those who did not. This PS deterioration however, was 
seen in only about 8.5% of the assessable patients who 
for the vast majority had a worsening from PS 0 to 
PS 1 (see Table III).
Correlation between toxicity and change in performance 
status at three years after randomisation
Table VI shows the univariate analysis relating the 
presence of any lung toxicity, lung fi brosis or evidence 
of cardiac disease within the fi rst three years to the 
risk of deterioration of the WHO PS. The results indi-
cate no statistically signifi cant relationship between 
lung toxicity or lung fi brosis and the risk of deteriora-
tion of the performance status. Cardiac diseases 
on the contrary seem signifi cantly correlated with 
a high risk of WHO PS deterioration (OR  3.71, 
CI: 1.90–7.24, p  0.0001). The impact of 
cardiac fi brosis could not be assessed because only 
11 patients were reported as having this event. None 
of these 11 patients had a deterioration of the PS at 
three years.
Discussion
Radiation therapy is an integral part of the multimo-
dality treatment of breast cancer. The Danish and 
the British Columbia trials have fi rmly established 
the survival advantage following radiotherapy in 
post mastectomy patients [10,16]. Furthermore, the 
EBCTCG meta-analysis has demonstrated that 
radiotherapy, besides improving local control rates, 
confers a survival benefi t in breast conservation 
treatment as well as in post mastectomy patients 
[15]. Although they showed the importance of loco-
regional control on survival outcomes, the Danish 
and British Columbia trials and the EBCTCG 
meta-analysis were unable to discern the direct con-
tribution from IM-MS treatment. It was noted as 
well that the survival gains associated with improve-
ments in loco-regional control may be diminished 
by RT-associated cardiac mortality [17–20]. The 
EORTC 22922/10925 trial investigates therefore if 
elective irradiation of the IM-MS chain improves 
overall survival at 10 years. 
In our report of the fi rst three years of follow-up 
in this study, we did not observe any difference 
Table III. WHO performance status at baseline and at year for the non-progressive patients
Performance status at 
year 3 Baseline Performance status








Missing 1 223 29 2 255
Performance status 0 5 1370 135 3 1513
Performance status 1 0 133 33 1 167
Performance status 2 0 4 0 1 5
Performance status 3 0 1 1 0 2
Performance status 4 0 2 0 0 2








Missing 4 224 30 0 258
Performance status 0 4 1361 114 4 1483
Performance status 1 3 134 33 1 171
Performance status 2 0 4 4 0 8
Performance status 3 0 1 0 0 1
Performance status 4 0 1 0 0 1
Total 11 1725 181 5 1922
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Effect OR 95% CI P-value OR 95% CI P-value
Treatment IM-MS vs. No IM-MS 1.02 0.77 1.35 0.89 1.12 0.68 1.86 0.66
Side left vs. right 0.98 0.75 1.30 0.92 1.15 0.69 1.91 0.60
Adjuvant hormonal 
therapy
Yes vs. None reported 0.56* 0.44 0.76 0.0001 0.99 0.59 1.67 0.97
Adjuvant chemotherapy Yes vs. No 1.26 0.90 1.75 0.18 N.A.
Age 45-55y vs. 45y 1.34 0.82 2.19 0.48 1.41 0.72 2.74 0.06
55-65 vs. 45 y 1.10 0.67 1.81 (df3) 0.66 0.29 1.54 (df3)
65 vs. 45 y 1.34 0.80 2.23 2.13 0.91 4.99
Type of surgery Breast conserving vs. 
Mastectomy
0.88 0.61 1.29 0.52 0.87 0.51 1.50 0.61
Tumour size (pathology) 1cm-2cm vs. 1 cm 0.95 0.66 1.37 0.66 1.98 0.59 6.62 0.71
2 cm-3cm vs. 1 cm 1.20 0.79 1.82 (df3) 1.70 0.49 5.89 (df3)
3 cm vs. 1 cm 108 0.60 1.94 1.98 0.55 7.17
pN pN vs. pN0 1.15 0.86 1.53 0.34 0.65 0.37 1.13 0.13
Pathological Stage Stage IIa vs. Stage I 0.98 0.70 1.37 0.41 1.19 0.54 2.64 0.60
Stage IIb vs. Stage I 1.33 0.89 1.97 (df3) 0.81 0.33 1.99 (df3)
Stage III vs. Stage I 1.35 0.71 2.56 0.81 0.32 2.06
Oestrogen receptor positive vs. negative 1.06 0.69 1.63 0.005 0.89 0.50 1.58 0.79
Unknown vs. negative 2.22 1.24 3.99 (df2) 1.39 0.31 6.36 (df2)
Progesterone receptor positive vs. negative 0.81 0.58 1.12 0.025 1.10 0.64 1.92 0.77
Unknown vs. negative 1.38 0.88 2.15 (df2) 0.77 0.25 2.29 (df2)
Combination of Receptors ER, PG-,unkn vs. ER, 
PG
1.32 0.92 1.88 0.50 0.63 0.29 1.38 0.66
PG, ER-,unkn vs. 
ER, PG
0.97 0.41 2.31 (df3) 1.01 0.30 3.37 (df2)
ER-, PG- vs. ER, PG 1.09 0.67 1.77 1.07 0.57 2.02
Menopausal status Post-Menopausal vs. 
Pre-menopausal
0.95 0.70 1.29 0.74 1.02 0.61 1.71 0.94
∗Signifi cant in multivariate model
between the two randomised groups in terms of 
“cardiac fi brosis” or “evidence of cardiac disease”. 
However, further follow-up is required to confi rm 
the absence of any deleterious impact of IM-MS 
treatment on cardiac function because late cardiac 
toxicity often appears 10 or even 15 years after treat-
ment [17–29] and because we observed already a 
signifi cant detrimental impact of the presence of 
cardiac disease on the PS of the patients. A limita-
tion of this study will however remain that there 
was no precise defi nition of cardiac fi brosis in the 
protocol and that there was no specifi c investigation 
planned.
Pulmonary fi brosis was observed in 0.9% and 
2.8% of patients in respectively the standard and 
IM-MS treatment arm. Lung toxicity of any kind 
was observed in only 1.3% vs. 4.3% of patients, 
representing an increase of only 57 cases of lung 
toxicity with IMMS irradiation. These results are in 
line with recent reports on pulmonary toxicity of 
breast radiotherapy [29–33]. This increased 
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treatments. Although we observed that neo-adju-
vant chemotherapy was given more frequently to 
young premenopausal patients with negative hor-
mone receptors and high disease stage, whereas 
hormonotherapy was given to postmenopausal 
older women, these patients did not all receive the 
adjuvant therapy. The observed effects of adjuvant 
therapies thus likely refl ect, for specifi ed patient 
subgroups, the benefi t of having actually received 
the adjuvant therapy that would be recommended 
in today’s practice (respectively neo-adjuvant 
chemotherapy in young patients and adjuvant hor-
monotherapy in post menopausal women). 
However, these protective effects can not be 
explained by an impact on tumour progression as 
the patients with early relapse were censored in this 
analysis. It is also important to note that the PS 
deteriorated in only 8.5% of the patients, mostly 
as a deterioration from PS 0 to PS 1.which may 
not be very clinical relevant. 
Conclusion
From this study, we conclude that IM-MS irradia-
tion seems well tolerated and does not signifi cantly 
impair WHO PS nor induces excess toxicity within 
the fi rst three years after treatment. Longer fol-
low-up is needed to further document cardiac toxic-
ity and the impact of IM-MS irradiation on clinical 
outcome.
statistically signifi cant difference between the toxic-
ity of the two treatment groups. Caution is however 
needed in the interpretation of these results the 
very large sample size of this study:  due to the very 
high statistical power, statistically signifi cant differ-
ences may not always be clinically relevant. It is 
important to note that the overall rate of lung tox-
icity remained below 5% in both treatment arms. 
In order to assess the impact of this toxicity on the 
patient’s every day living, we correlated the changes 
of PS to the treatment arm. Despite the observed 
increase of lung toxicity with IM-MS irradiation, 
we could not demonstrate any signifi cant difference 
in the risk of decreased PS between the randomised 
treatments nor could we demonstrate any signifi -
cant correlation between the deterioration of the PS 
and the risk of lung toxicity. This suggests that these 
lung toxicities remain mainly subclinical or disap-
pear with follow-up as is often seen with limited to 
moderate radio-pneumonitis. 
The other reported toxicities are all well known 
toxicities of breast cancer radiotherapy and were not 
signifi cantly increased with IM-MS irradiation.
An unexpected observation was that patients 
treated with neo-adjuvant chemotherapy had a 
lower risk of worsening their PS. A similar risk 
reduction was for patients who received adjuvant 
hormonotherapy. It is important to recognise that 
the trial protocol contained no strict guidelines as 
to which patients were to receive these adjuvant 
Table V. Infl uence of various parameters in the multivariate analysis on WHO performance status deterioration
Without neo-adjuvant chemotherapy
Effect OR 95% CI P-value
Neo-Adjuvant chemotherapy Yes vs. No 0.30 0.18 0.52 0.0001
Adjuvant hormonal therapy 
(if no neoadjuvant CT)
Yes vs. None reported 0.53 0.38 0.74 0.0002
Adjuvant hormonal therapy
(if neoadjuvant CT)
Yes vs. None reported 0.90 0.50 1.61 0.72
Age 45-55y vs. 45y 1.42 0.90 2.25 0.087
55-65 vs. 45 y 1.20 0.67 2.16 (df3)
65 vs. 45 y 1.77 0.96 3.24
Pathological Stage Stage IIa vs. Stage I 1.22 0.89 1.68 0.44
Stage IIb vs. Stage I 1.35 0.92 1.99 (df3)
Stage III vs. Stage I 1.20 0.71 2.04
Combination of Receptors ER, PG-, unkn vs. ER, PG 1.16 0.84 1.61 0.087 
PG, ER-, unkn vs. ER, PG 0.87 0.43 1.35 (df3)
ER-, PG- vs. ER, PG 0.87 0.57 2.25
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N (%) N (%) OR 95% CI P-value
Any lung toxicity   
 No 2972 (91.5)  276 (8.5) 
 Yes  84 (90.3)  9 (9.7) 1.19 0.59-2.41 0.62
Lung Fibrosis (to year 3)   
 No 2996 (91.5)  280 (8.5) 
 Yes  56 (91.8)  5 (8.2) 1.02 0.40-2.59 0.96
 Missing  4 (100.0)  0 (0.0) 
Cardiac Fibrosis (to year 3)   
 No 3038 (91.4)  285 (8.6) Too small
 Yes  11 (100.0)  0 (0.0) sample for
 Missing  7 (100.0)  0 (0.0) testing
Evidence of cardiac disease (to year 3)   
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